Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy - A [123I]CNS-1261 SPET study

Psychopharmacology

Volumn 197, Issue 3, 2008, Pages 401-408

  Stone, James M ^a   Erlandsson, Kjell ^b   Arstad, Erik ^b   Squassante, Lisa ^c   Teneggi, Vincenzo ^c   Bressan, Rodrigo A ^a   Krystal, John H ^d,e   Ell, Peter J ^b   Pilowsky, Lyn S ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GSK   (Italy)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Glutamate; Ketamine; Negative symptoms; NMDA; Psychosis; Schizophrenia; SPECT

Indexed keywords

DIZOCILPINE; KETAMINE; N (1 NAPHTHYL) N' (3 IODOIODOPHENYL) N' METHYLGUANIDINE I 125; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SODIUM CHLORIDE; TRACER;

ADULT; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; BRAIN REGION; BRIEF PSYCHIATRIC RATING SCALE; CONTROL GROUP; CORRELATION ANALYSIS; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INFUSION; MALE; NEGATIVE SYNDROME; NORMAL HUMAN; POSITIVE SYNDROME; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; BRIEF PSYCHIATRIC RATING SCALE; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANIDINES; HUMANS; INFUSIONS, INTRAVENOUS; IODINE RADIOISOTOPES; KETAMINE; MALE; PREFRONTAL CORTEX; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SINGLE-BLIND METHOD; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 43149093378     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-1047-x     Document Type: Article

References (32)

1. Aalto S, Ihalainen J, Hirvonen J, Kajander J, Scheinin H, Tanila H, Nagren K, Vilkman H, Gustafsson LL, Syvalahti E, Hietala> J (2005) Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) 182:375-383
2. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29:142-147
3. 123I]CNS 1261. Nucl Med Biol 31:155-164
4. Coyle JT, Tsai G, Goff D (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 1003:318-327
5. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J (2001) A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 24:43-49
6. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM (1997) Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333:99-104
7. 123I]CNS 1261-a potential SPET tracer for the NMDA receptor. Nucl Med Biol 30:441-454
8. Holcomb HH, Lahti AC, Medoff DR, Weiler M, Tamminga CA (2001) Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 25:165-172
9. Javitt DC (2006) Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 19:151-157
10. Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 7:837-844
11. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr., Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
12. Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, Macdougall L, Abi-Saab W, D'Souza DC (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62:985-994
13. 11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab 14:995-1010
14. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117:697-706
15. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307
16. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-1927
17. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007
18. Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533
19. Owens J, Tebbutt AA, McGregor AL, Kodama K, Magar SS, Perlman ME, Robins DJ, Durant GJ, McCulloch J (2000) Synthesis and binding characteristics of N-(1-naphthyl)-N′-(3-[(125)I]-iodophenyl)-N′-methylguanidine ([(125)I]-CNS 1261): a potential SPECT agent for imaging NMDA receptor activation. Nucl Med Biol 27:557-564
20. Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH, Ell PJ (2006) First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11:118-119
21. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, Brooks WM (2005) Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 162:394-396
22. Seeman P, Ko F, Tallerico T (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10:877-883
23. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S (2001) Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 24:330-334
24. 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18-25
25. Stone JM, Pilowsky LS (2006) Psychopathological consequences of ketamine. Br J Psychiatry 189:565-566
26. Stone JM, Erlandsson K, Arstad E, Bressan RA, Squassante L, Teneggi V, Ell PJ, Pilowsky LS (2006) Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo. Nucl Med Biol 33:239-243
27. 1H MRS). Pharmacopsychiatry 38:214-219
28. Takeuchi R, Yonekura Y, Matsuda H, Konishi J (2002) Usefulness of a three-dimensional stereotaxic ROI template on anatomically standardised 99mTc-ECD SPET. Eur J Nucl Med Mol Imaging 29:331-341
29. Tuominen HJ, Tiihonen J, Wahlbeck K (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72:225-234
30. Ventura J, Nuechterlein KH, Subotnik KL, Gutkind D, Gilbert EA (2000) Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res 97:129-135
31. Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56:495-507
32. 11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34:35-43